Press Release: April 03, 2020
The world's leading chemical vendor BOC Sciences started to supply top class active pharmaceutical ingredients (APIs) and excipients for drug formulation purposes years ago, aiming to provide an integrated, one-stop solution for large pharmaceutical companies that has outsourcing needs. The company recently announces to promote four APIs, namely Daunorubicin, Doxorubicin, Epirubicin and Valrubicin for cancer treatment.
To cure various diseases like cancer, neurologic disease, cardiovascular disease, which pose major threats to human beings, high quality APIs are of critical importance in drug formulation. "For pharmaceutical companies trying to explore more effective ways in cancer treatment, Daunorubicin hydrochloride, Doxorubicin hydrochloride, Epirubicin hydrochloride and Valrubicin hydrochloride are what we highly recommended," says a senior scientist from BOC Sciences.
Daunorubicin is a chemotherapeutic medication used to treat cancer, acute myeloid leukemia, (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia, (CML) and Kaposi's sarcoma. It was approved for medical use in 1979 in the United States.
Also a chemotherapeutic drug, doxorubicin slows or blocks the growth of cancer cells by blocking an enzyme called topoisomerase. Approved for medical use in the United States in 1974, doxorubicin is commonly used in the treatment of some leukemia and Hodgkin's lymphoma, bladder cancer, breast cancer, etc.
Although doxorubicin is the most popular anthracycline, epirubicin is a preferred choice in some chemotherapy regimens as it appears to cause fewer side effects. In 1999, epirubicin received FDA approval as a component of adjuvant therapy in node-positive patients.
Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, which can affect a variety of interrelated biological functions, most of which are involved in nucleic acid metabolism.
"We have successfully developed volume production of these four APIs at our established GMP facility, which is expecting FDA audit in 2020. Three APIs, Daunorubicin HCl, Doxorubicin HCl and Epirubicin HCl, have obtained USDMF and EUDMF," further adds the scientist.
In addition to the four API compounds mentioned above, BOC Sciences also provides a large number of pharmaceutical excipients alongside to further meet the needs arising from drug formulation, in a hope to streamline the outsourcing process for clients in their research and production.
For more information about the four API products-Daunorubicin, Doxorubicin, Epirubicin and Valrubicin as well as pharmaceutical excipients at BOC Sciences, please visit https://www.bocsci.com or email us at firstname.lastname@example.org.
About BOC Sciences
Over the last decade, BOC Sciences has devoted tremendously in order to become a reliable helper for clients world-wide in the field of drug discovery and development. To this end, this company has been supplying quality chemicals in the field of biochemistry and life sciences, covering the range of inhibitors, metabolites, pharmaceutical excipients, impurities, intermediates, ADCs, chiral compounds, stem cell molecules, carbohydrates, nucleosides, nucleotides, etc.